Otsuka Pharmaceutical Co. Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Otsuka Pharmaceutical Co. Ltd.
The French drugmaker has halted a pivotal trial of venglustat in autosomal dominant polycystic kidney disease, a few months after the drug failed as a treatment for Parkinson’s disease. Sanofi will go back to focusing on the therapy's potential in lysosomal storage diseases.
Growing trend of linking product websites to telehealth services raises regulatory concerns. Virtual interactions with healthcare providers might necessitate new FDA guidance, lawyers note at FDLI annual meeting.
Solid tumor-focused Taiho Oncology teams with hematological cancer specialist Astex under the Otsuka umbrella. Taiho also performs US/Canada commercialization for all three firms.
Denmark’s Lundbeck is aiming to build up use of its latest neurological, the long-acting migraine preventative, Vyepti, now that US healthcare is emerging from COVID-19-related restrictions, but is facing headwinds from loss of exclusivity on Northera.
- Medical Devices
- OTC, Consumer
In Vitro Diagnostics
- Chemistry, Immunoassay